Ketamine for bipolar depression: an updated systematic review.

"Declarations Ethics approval and consent to participate: Not applicable.Consent for publication: Not applicable.Author contributions:Farhan Fancy: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Validation; Visualization; Writing – original draft; Writing – review & editing.Sipan Haikazian: Data curation; Formal analysis; Investigation; Methodology; Writing – original draft; Writing – review & editing.Danica E. Johnson: Formal analysis; Writing – review & editing.David C. J. Chen-Li: Formal analysis; Writing – review & editing.Anastasia Levinta: Formal analysis; Writing – review & editing.Muhammad I. Husain: Formal analysis; Supervision; Writing – review & editing.Rodrigo B. Mansur: Formal analysis; Supervision; Writing – review & editing.Joshua D. Rosenblat: Conceptualization; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Writing – review & editing.Funding: The authors received no financial support for the research, authorship, and/or publication of this article.Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. JDR has received research grant support from the Canadian Institute of Health Research (CIHR), Physician Services Inc (PSI) Foundation, Labatt Brain Health Network, Brain and Cognition Discovery Foundation (BCDF), Canadian Cancer Society, Canadian Psychiatric Association, Academic Scholars Award, American Psychiatric Association, American Society of Psychopharmacology, University of Toronto, University Health Network Centre for Mental Health, Joseph M. West Family Memorial Fund and Timeposters Fellowship and industry funding for speaker/consultation/research fees from Janssen, Allergan, Lundbeck, Sunovion, and COMPASS. He is the Chief Medical and Scientific Officer of Braxia Scientific and the medical director of the Canadian Rapid Treatment Centre of Excellence (Braxia Health). Dr. MIH receives research support from the Brain and Behavior Research Foundation, Canadian Institutes of Health Research (CIHR), CAMH Foundation, Grand Challenges Canada, the PSI Foundation, and the University of Toronto. He has conducted contracted research for COMPASS Pathfinder Limited and provided consultancy to Mindset Pharma, PsychEd Therapeutics, and Wake Network.Availability of data and materials: All data collected is presented in the main manuscript. Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. JDR has received research grant support from the Canadian Institute of Health Research (CIHR), Physician Services Inc (PSI) Foundation, Labatt Brain Health Network, Brain and Cognition Discovery Foundation (BCDF), Canadian Cancer Society, Canadian Psychiatric Association, Academic Scholars Award, American Psychiatric Association, American Society of Psychopharmacology, University of Toronto, University Health Network Centre for Mental Health, Joseph M. West Family Memorial Fund and Timeposters Fellowship and industry funding for speaker/consultation/research fees from Janssen, Allergan, Lundbeck, Sunovion, and COMPASS. He is the Chief Medical and Scientific Officer of Braxia Scientific and the medical director of the Canadian Rapid Treatment Centre of Excellence (Braxia Health). Dr. MIH receives research support from the Brain and Behavior Research Foundation, Canadian Institutes of Health Research (CIHR), CAMH Foundation, Grand Challenges Canada, the PSI Foundation, and the University of Toronto. He has conducted contracted research for COMPASS Pathfinder Limited and provided consultancy to Mindset Pharma, PsychEd Therapeutics, and Wake Network."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."